Troglitazone attenuates hypoxia-induced injury in cultured term human trophoblasts

Troglitazone attenuates hypoxia-induced injury in cultured term human trophoblasts
复制标题

DOI:
10.1016/j.ajog.2004.05.009
复制
发表时间:
2004-12-01
影响因子:
9.8
通讯作者:
Nelson, M
Nelson, M
中科院分区:
医学1区
文献类型:
--
作者:
Elchalal, U;Humphrey, RG;Nelson, M

文献摘要

被引文献

相似文献

目的:本研究的目的是检验噻唑烷二酮曲格列酮(一种过氧化物酶体增殖物激活受体-γ配体)减弱缺氧诱导的滋养层损伤的假设。在细胞收获前,在20%氧气(标准条件)或1%氧气(缺氧条件)中,在存在或不存在10 μ mol/L曲格列酮的情况下,将来自4个足月人胎盘的细胞滋养层培养不同的时间。中β-人绒毛膜促性腺激素和人胎盘乳。用酶联免疫吸附试验分析。细胞角蛋白-18裂解产物染色定量细胞凋亡,p53蛋白的表达进行了检查,通过Western blot analysis.Results:β-人绒毛膜促性腺激素和人胎盘催乳素水平大于或等于2倍高曲格列酮暴露的细胞在缺氧16小时。与载体对照细胞相比(P <0.05)。缺氧16 h内,曲格列酮处理的滋养细胞凋亡指数降低≥ 30%(P <0.001),p53蛋白表达降低2倍(P <0.02),缺氧24 h后,二者无明显差异。(C)2004年爱思唯尔公司All rights reserved.
Objective: The purpose Of this Study was to test the hypothesis that the thiazolidinedione troglitazone, a peroxisome proliferator activated receptor-gamma ligand, attenuates hypoxia-induced trophoblast injury.Study design: Cytotrophoblasts from 4 term human placentas were cultured in the presence or absence of 10 mumol/L troglitazone in either 20% oxygen (standard conditions) or 1% oxygen (hypoxic conditions) for variable periods before cell harvest. Medium beta-human chorionic gonadotropin and human placental lacto.-en were analyzed by enzyme-linked immunosorbent assay. Apoptosis was quantified by cytokeratin-18 cleavage products staining; p53 expression was examined by Western blot analysis.Results: beta-human chorionic gonadotropin and human placental lactogen levels were greater than or equal to2-fold higher in troglitazone-exposed cells at 16 hours of hypoxia. compared with vehicle control cells (P < .05). The apoptotic index was reduced by greater than or equal to 30% (P < .001), and the expression of p53 was 2-fold lower (P < .02) in troglitazone-exposed cells under hypoxia for less than or equal to16 hours but not different after >24 hours of low oxygen.Conclusion: Troglitazone attenuates the influence of acute hypoxia on Cultured term human trophoblasts. (C) 2004 Elsevier Inc. All rights reserved.